Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by newtoinvesting1on Oct 13, 2019 9:15pm
96 Views
Post# 30227282

baystreeter and AMG comments

baystreeter and AMG commentsHi,

I am just trying to figure out the science or how this is done.  I'm not new to investing really but to these small bio plays I am.  Now I know why.  I'm concerned about this one. 

AMG said that everything depends on CSO and his science.... and baystreeter said DMA went from $125M to a big loss on his watch and what is more concerning is how they left?  I looked up 11/28/2016 press release: The Company also announced the resignation of Mark Williams as Vice President of Research, effective today, to pursue other opportunities. The Company will continue working with Mark as a consultant.

Any insight into this? Maybe he had a better offer - good scientists are always recruited away to other companies or research opportunities so maybe this is a good thing?? 

Just my 2 cents on this but getting the stock at these prices could be a deal. Not looking to get rich but a nice bump to 25 cents isn't asking too much is it?

Thank you for anyones thought and happy investing. 

JT.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities